Under the terms announced for the sale, Theravance shareholders are slated to receive $176.00 per share in cash, supplemented by one contingent value right. Monteverde & Associates, a firm recognized in the 2025 ISS Securities Class Action Services Report, is examining the potential impact of these terms on equity holders. The firm is inviting stockholders to review the details of the agreement to determine if the compensation adequately reflects the company's market position.
Monteverde & Associates Launches Investigation into Theravance Sale
Is the proposed acquisition of Theravance Biopharma by Zymeworks Inc. truly in the best interest of shareholders? New York-based Monteverde & Associates PC has initiated a formal investigation into the transaction, questioning whether the deal’s structure provides fair value to investors currently holding NASDAQ: TBPH stock.
Investors concerned about the fairness of the sale are encouraged to reach out to the firm for a consultation. Juan Monteverde, the lead attorney on the case, can be contacted at jmonteverde@monteverdelaw.com or via telephone at (212) 971-1341. The firm maintains that these inquiries are conducted without cost or obligation to the shareholders involved.
:max_bytes(150000):strip_icc()/blue-power-meters-161049597-58ae35b05f9b58a3c9346a59.jpg)
Comments (0)
No comments yet. Be the first!